



ASX Release

Acrux FY23 Results webinar

Melbourne, Australia; 25 August 2023

Acrux Limited (ASX:ACR, “Acrux” or the “Company”) will host an Investor Webinar where management will present the results for the Company for the financial year ended 30 June 2023. Questions that are sent in advance of the webinar to info@acrux.com.au or michael.kotsanis@acrux.com.au will be addressed immediately after the presentation.

Investor Webinar details:

Date: Thursday 31 August, 2023

Time: 10:00 Melbourne, Sydney, Brisbane

Topic: Acrux FY23 results webinar

Please click the link below to join the webinar:

<https://us02web.zoom.us/j/81237485907>

Or One tap mobile :

+61861193900,,81237485907# Australia

+61871501149,,81237485907# Australia

Webinar ID: 812 3748 5907

International numbers available: <https://us02web.zoom.us/j/81237485907>



Approved for release by the Acrux Board of Directors.

For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director
P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au